Activation of protein kinase C (PKC) is implicated as an important mechanism by which diabetes causes vascular complications. We have recently shown that a PKC ␤ inhibitor ameliorates not only early diabetes-induced glomerular dysfunction such as glomerular hyperfiltration and albuminuria, but also overexpression of glomerular mRNA for transforming growth factor ␤1 (TGF-␤1) and extracellular matrix (ECM) proteins in streptozotocin-induced diabetic rats, a model for type 1 diabetes. In this study, we examined the long-term effects of a PKC ␤ inhibitor on glomerular histology as well as on biochemical and functional abnormalities in glomeruli of db/db mice, a model for type 2 diabetes. Administration of a PKC ␤ inhibitor reduced urinary albumin excretion rates and inhibited glomerular PKC activation in diabetic db/db mice. Administration of a PKC ␤ inhibitor also prevented the mesangial expansion observed in diabetic db/db mice, possibly through attenuation of glomerular expression of TGF-␤ and ECM proteins such as fibronectin and type IV collagen. These findings provide the first in vivo evidence that the long-term inhibition of PKC activation in the renal glomeruli can ameliorate glomerular pathologies in diabetic state, and thus suggest that a PKC ␤ inhibitor might be an useful therapeutic strategy for the treatment of diabetic nephropathy
Diabetic nephropathy is a leading cause of endstage renal disease (ESRD), accounting for 35% of all new cases requiring dialysis therapy in Western (1) and Asian countries. Clinical studies such as the Diabetes Control and Complications Trial (DCCT) in subjects with type 1 diabetes (2) and UK Prospective Diabetes Study (UKPDS) in subjects with type 2 diabetes (3) clearly link hyperglycemia to vascular complications, including diabetic nephropathy. Furthermore, the maintenance of normoglycemia for 10 years by pancreatic transplantation regressed glomerular pathological changes in eight subjects with type 1 diabetes (4). However, the intensive treatment in both DCCT and UKPDS failed to maintain normoglycemia in most subjects with diabetes. Therefore, an understanding of the hyperglycemia-related molecular pathogenesis of diabetic nephropathy is needed to provide further insight into therapeutic strategies for diabetic kidney disease.
Multiple biochemical mechanisms by which the diabetic state (hyperglycemia) causes glomerular dysfunction have been proposed, including activation of protein kinase C (PKC) extracellular-regulated protein kinase (ERK) pathway (5) (6) (7) (8) , enhanced polyol pathway (9, 10) related to myo-inositol depletion (10, 11) , altered redox state, and oxidative stress (12, 13) , overproduction of advanced glycation end products (14) , and enhanced growth factor and cytokine production (15) . The inappropriate activation of PKC has been implicated as a putative mediator in the pathogenesis of diabetic nephropathy based on evidence in both in vivo experimental animal models for type 1 diabetes and in vitro studies in cultured glomerular cells (5) (6) (7) (8) ).
An increase in de novo synthesis of diacylglycerol generated from glycolytic intermediates and the resulting activation of PKC, followed by the activation of ERK, were found in renal glomeruli (7, 16 -20) of streptozotocin (STZ)-induced diabetic animals as well as in vascular cells such as glomerular mesangial cells (18, 21, 22) . Furthermore, a variety of glomerular and mesangial cell dysfunction caused by diabetes or high glucose was mimicked by phorbol esters, which directly activate PKC, and abrogated by PKC inhibitors, implicating PKC activation in the pathogenesis of glomerular and mesangial dysfunction in diabetes (7, 23, 24) . We have recently shown that short-term treatment with orally administered PKC ␤ inhibitor (LY333531) can prevent early diabetes-induced glomerular dysfunction such as glomerular hyperfiltration, albuminuria, and enhanced mRNA expression of transforming growth factor ␤1 (TGF-␤1) and extracellular matrix (ECM) proteins in STZ-induced, insulin-deficient diabetic rats, a rodent model for type 1 diabetes (18, 19) . However, the effect of long-term PKC inhibition on diabetesinduced glomerular pathology in preclinical models of diabetes remains to be clarified.
The chronic renal response to diabetes is characterized by histological abnormalities such as glomerular hypertrophy, basement membrane thickening, and mesangial expansion. Of these, the progression of mesangial expansion is considered to be responsible for the obliteration of capillary lumen leading to glomerulosclerosis and ESRD (25) (26) (27) . We examined whether chronic administration of a PKC ␤ inhibitor could prevent the glomerular mesangial expansion in a preclinical model of diabetes. Since type 2 diabetes is the most prevalent clinical form not only in Asian countries but also in Western societies, we used diabetic db/db mice, a rodent model for type 2 diabetes. Our findings provide evidence for the beneficial effect of PKC ␤ inhibition on glomerular mesangial expansion as well as on other glomerular dysfunction such as albuminuria in diabetic db/db mice, a rodent model for type 2 diabetes.
MATERIALS AND METHODS

Animals and experimental design
Male db/db mice, a rodent model for type 2 diabetes, and their nondiabetic db/m littermates, purchased from the Clea Co. Ltd. (Tokyo, Japan), were randomly divided into four groups as follows: nondiabetic db/m; nondiabetic db/m treated with a PKC ␤ inhibitor (LY333531); diabetic db/db; and diabetic db/db treated with a PKC ␤ inhibitor. The db/db mice were confirmed as being diabetic by measuring blood glucose levels, which exceeded 16.7 mM at the age of 9 wk. The PKC ␤ inhibitor was given orally mixed in chow (10 mg/kg body weight/day) from the age of 9 wk to 25 wk. Blood glucose levels and body weight were determined weekly in all animals. Blood pressure was measured by a tail cuff method at the age of 16 wk. All experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of laboratory Animals and were approved by the Animal Care Committees of Shiga University of Medical Science.
Isolation of glomeruli and the measurement of glomerular PKC activity
Sixteen weeks after treatment with the PKC ␤ inhibitor (25 wk of age), renal glomeruli were isolated by sieving with stainless steel and nylon meshes, as described previously (28) . In brief, bilateral kidneys were dissected, homogenized in ice-cold RPMI1640 media containing 20 mM HEPES (pH 7.4) after removing the capsules, and passed through sieves of various sizes to isolate the glomeruli. Isolated glomeruli were washed twice with RPI1640 media containing 20 mM HEPES (pH 7.4) and once with a salt solution (137 mM NaCl, 5.4 mM KCl, 0.3 mM sodium phosphate, 0.4 mM potassium phosphate, 5.5 mM glucose, 10 mM MgCl 2 , 25 mM ␤-glycerophosphate, 5 mM EGTA, 2.5 mM CaCl 2 , and 20 mM HEPES, pH 7.4). PKC activity was determined by a modified in situ PKC assay using isolated glomeruli that was validated as described previously (29) . The glomeruli were incubated with a salt solution for 15 min in the presence or absence of 100 M PKC-specific substrate, RTLRRL, after the addition of 5 mg/ml digitonin (final concentration, 50 g/ml) and 1 mM ATP (final concentration, 100 M) mixed with ␥-[
32 P]ATP (Ͻ1500 cpm/pmol). The reaction was stopped by 5% trichloroacetic acid (TCA). Aliquots of the reaction were spotted on 2.5 ϫ 2.5 cm phosphocellulose paper (Whatman P81, Maidstone, U.K.) and washed in three changes of 75 mM phosphoric acid and once with 75 mM sodium phosphate (pH 7.5). Radioactivity of phosphorylated substrate was determined by liquid scintillation counting. Protein content of each sample was measured by the method of Bradford (30) . Glomerular PKC activity was normalized by the corresponding protein content.
Sixteen weeks after treatment with the PKC ␤ inhibitor (25 wk of age), 24 h urine samples were collected in metabolic cages for 2 consecutive days. Albumin in urine was measured by a competitive ELISA (Albuwell M, Exocell Inc., Philadelphia, Pa.) according to the manufacturer's instruction.
Histological and morphometric procedures
Sixteen weeks after treatment with the PKC ␤ inhibitor (25 wk of age), mice were deeply anesthetized by an intraperitoneal injection of 50 mg/kg body weight pentobarbital sodium (Abbott laboratories, Chicago, Ill.). Inferior vena cava and abdominal aorta were exposed, and 24 gauge needles were inserted into the former and the latter caudal to the renal vessels, respectively. After perfusion with ice-cold Ringer solution, the kidneys were perfused with 10% buffered formalin (FM), excised, decapsulated, weighed, and immersed in 10% FM. Both kidneys were embedded in paraffin and sections of 4 m thickness were cut perpendicular to the long axis of the kidney for morphometric and immunohistochemical analysis.
For morphometric analysis of the glomeruli, sections were stained with periodic acid-Sciff (PAS). To quantify mesangial expansion, sections were coded and read by an observer unaware of the experimental protocol applied. In each animal of the four experimental groups, 20 glomeruli cut at their vascular pole were used for a morphometric analysis. The extent of increase in mesangial matrix (defined as mesangial area) was determined by the presence of PAS-positive and nuclei-free area in the mesangium; the glomerular area was also traced along the outline of capillary loop using a com-puter-assisted color image analyzer LUZEX F (Nikon, Tokyo, Japan).
The tissue fixed with 10% FM was used for an immunohistochemical study of fibronectin, type IV collagen, and transforming growth factor (TGF)-␤ using specific antibodies: a polyclonal anti-mouse fibronectin antibody; A852/R5H (Biogenesis, Poole, England); a polyclonal anti-mouse collagen IV antibody (Becton Dickinson Labware, Bedford, Pa.); and a polyclonal anti-TGF-␤ antibody that recognizes all of the TGF-␤ variants (R&D Systems Inc., Minneapolis, Minn.). Immunostaining was performed by the streptavidin-biotin immunoperoxidase method using a histofine SAB-PO kit (Nichirei, Tokyo, Japan) according to the instructions of manufacturer. Immunoreactive products were visualized using diaminobenzidine as a chromogen and counterstained with either methyl green or hematoxylin. Control staining was performed using nonimmune serum and the appropriate secondary antibody. To check the specificity of immunohistochemical findings for fibronectin, type IV collagen, and TGF-␤, absorption tests were performed; sections were preincubated in the serum containing corresponding antibodies in the presence of fivefold molar excess of the peptide used for immunization, then processed for further immunohistochemical staining as described above.
To evaluate the immunostaining for fibronectin, type IV collagen, and TGF-␤, a total of 20 randomly chosen glomeruli per mouse were coded and graded semiquantitatively in a double-blind manner by two independent observers. The degree of fibronectin and type IV collagen expression in five mice from each group was graded as follows: 0, absent staining to 5%; 1, 5 to 25%; 2, 25 to 50%; 3, 50 to 75%, 4, Ͼ75% (31). The TGF-␤ expression in five mice from each group was semiquantified as follows: 0, all glomerular cells and mesangial matrix negative; 1, weak staining of 1 or 2 cells and/or Ͻ25% of the glomerular tuft weakly positive; 2, intense staining of 1 or 2 cells, and/or weak staining of three or more cells and 25 to 50% of the glomerular tuft positive; 3, intense cytoplasmic staining of three or more cells and/or Ͼ50% of the glomerular tuft positive (32) .
Statistical analysis
All data are presented as mean Ϯ standard deviation. Comparisons among four experimental groups were analyzed by one-way analysis of variance (ANOVA), followed by either Scheffe's test or Bonferroni/Dunn's test to evaluate statistical difference between two groups. P values less than 0.05 were defined as statistically significant.
RESULTS
Oral administration of a PKC ␤ inhibitor reduces urinary albumin excretion and normalizes glomerular PKC activity in db/db mice
The db/db mice, a model for type 2 diabetes, exhibited hyperglycemia associated with obesity as compared with their nondiabetic db/m littermates at 9 wk of age ( Table 1) . Throughout the experimental periods (9 -25 wk of age), blood glucose levels were consistently higher in db/db mice than in db/m mice. Mean blood pressure measured at the age of 16 wk by a tail cuff was not affected by treatment with a PKC ␤ inhibitor: 117 Ϯ 11 mmHg in db/m (nϭ5) vs. 125 Ϯ 6 mmHg in db/m treated with a PKC ␤ inhibitor (nϭ5), not significant; 110 Ϯ 8 mmHg in db/db (nϭ4) vs. 104 Ϯ 10 mmHg in db/db treated with a PKC ␤ inhibitor (nϭ5), not significant. Body weights were also greater in db/db mice than in db/m mice. Kidney weights were slightly, but not significantly, increased in db/db mice as compared to db/m mice. Kidney-to-body weight ratio differed significantly between nondiabetic db/m and diabetic db/db mice (data not shown), since the diabetic db/db mice exhibited greater body weights. Long-term oral treatment with LY333531, a PKC ␤ inhibitor, at a dose of 10 mg/kg body weight/day did not affect blood glucose levels, body weight, or kidney weight in either nondiabetic db/m or diabetic db/db mice (Table 1) .
Since glomerular PKC activity has been shown to be increased in the glomeruli of STZ-induced, insulin-deficient diabetic rats, a rodent model for type 1 diabetes (7, 16 -19, 29) , we tested whether glomerular PKC activity was increased in db/db mice, a model for type 2 diabetes. At 25 wk of age, PKC activity in the glomeruli of the diabetic db/db mice was 180% relative to that observed in the nondiabetic db/m mice (Fig. 1) . Treatment with PKC ␤ inhibitor reduced PKC activity to normal levels ( Urinary albumin excretion, which is one of parameters of glomerular dysfunction in diabetes, was also measured. Urinary albumin excretion was significantly increased in db/db mice as compared with that in db/m mice at the age of 25 wk (Fig. 2) . Administration of the PKC ␤ inhibitor significantly abrogated the increased urinary albumin excretion rates in db/db mice (Fig. 2) . Urinary albumin excretion rates in db/db mice treated with the PKC ␤ inhibitor were nearly comparable with those in nondiabetic db/m mice (Fig. 2) . The PKC ␤ inhibitor did not affect urinary albumin excretion in db/m mice.
PKC ␤ inhibitor significantly ameliorates mesangial expansion and prevents the enhanced expression of ECM proteins and TGF-␤
One of the most striking characteristics of diabetic nephropathy is mesangial expansion, which results from accumulation of ECM proteins (33) (34) (35) . Since mesangial expansion is strongly associated with a decrease in filtration surface and ultimately ESRD in human diabetics (25) (26) (27) , we tested whether the long-term treatment with a PKC ␤ inhibitor could reduce mesangial expansion in diabetic db/db mice. The glomerular appearance in db/db mice showed (Fig. 3, panel A vs. panel C) . This mesangial expansion in db/db mice was prevented by the treatment with the PKC ␤ inhibitor for 16 wk (Fig. 3D) . The PKC ␤ inhibitor did not alter the glomerular appearance in db/m mice (Fig. 3B) . Mesangial expansion was further quantitated by a morphometrical analysis. The PAS positive and nuclei-free mesangial area in the glomeruli of db/db mice was 441% of that in db/m mice (Fig. 4A) . The treatment with the PKC ␤ inhibitor reduced the extent of mesangial expansion by 48% in db/db mice, but did not affect mesangial area in db/m mice (Fig. 4A) . Total glomerular area by tracing along the outline of capillary loop was also increased in db/db mice compared with that in db/m mice, but PKC ␤ inhibitor did not affect this parameter (Fig. 4B) . Thus, the relative mesangial area calculated by mesangial area/total glomerular area ratio was increased by 320% in db/db mice as compared with db/m mice. Administration of the PKC inhibitor significantly ameliorated the increase in the relative mesangial area in db/db mice compared with that in untreated db/db mice (Fig. 4C) .
Consistent with the results of mesangial expansion, the diabetic db/db mice demonstrated overexpression of ECM components such as fibronectin and type IV collagen as compared with db/m mice ( Fig. 5A and Fig. 6A vs. Fig. 5C and Fig. 6C , respectively). Administration of the PKC ␤ inhibitor also reduced the overexpression of fibronectin and type Figure 2 . Effect of PKC ␤ inhibition on the urinary albumin excretion rate of nondiabetic db/m and diabetic db/db mice. A 24 h urine sample for each mouse was collected in metabolic cages on 2 consecutive days 16 wk after the start of this experiment. Urine samples were processed to measure urinary albumin concentration using a competitive ELISA. Data were average of urinary albumin excretion of 2 consecutive days and were shown as mean Ϯ standard deviation from 6 -9 mice. Numbers of mice from each group were denoted below each column. *P Ͻ 0.05 vs. other group. Effect of PKC ␤ inhibition on glomerular PKC activity of nondiabetic db/m and diabetic db/db mice. The mice were divided into 4 groups: db/m, db/m treated with a PKC ␤ inhibitor (10 mg/kg body weight/day), db/db, db/db treated with a PKC ␤ inhibitor (10 mg/kg body weight/day). Glomeruli were isolated from each group 16 wk after initiating treatment. Glomerular PKC activity was measured by in situ PKC assay described in Materials and Methods and was normalized by corresponding protein content. One experiment was performed using isolated glomeruli from 2 kidneys of a mouse. Data was shown as mean Ϯ standard deviation from 6 -9 mice. *P Ͻ 0.05 vs. other group.
IV collagen in the glomeruli of db/db mice to levels comparable to those observed in db/m mice ( Fig. 5D and Fig. 6D vs. Fig. 5A and Fig. 6A, respectively) . Expression of TGF-␤, one of the possible mediators responsible for the overexpression of ECM proteins in diabetes (15, 36) was also enhanced in the glomeruli of db/db mice (Fig. 7C) . Treatment with the PKC ␤ inhibitor reduced TGF-␤ overexpression in db/db mice (Fig. 7D) . Semiquantitative scores for fibronectin, type IV collagen, and TGF-␤ expression increased from 1.4 Ϯ 0.5, 1.3 Ϯ 0.5, 1.3 Ϯ 0.5 in db/m mice to 3.4 Ϯ 0.7, 3.6 Ϯ 0.5, 2.8 Ϯ 0.4 in db/db mice, respectively (db/m vs. db/db, nϭ5, PϽ0.05). Treatment with the PKC ␤ inhibitor again reduced scores for fibronectin, type IV collagen, and TGF-␤ expression to 1.8 Ϯ 0.5, 1.8 Ϯ 0.5, 1.5 Ϯ 0.7, respectively (db/db vs. db/db treated with a PKC ␤ inhibitor, nϭ5, PϽ0.05).
DISCUSSION
Two important findings were observed in the present study. First, PKC activity was enhanced in glomeruli of diabetic db/db mice, a model for type 2 diabetes. More important, it was clearly demonstrated that long-term inhibition of PKC by the oral treatment with a PKC ␤ inhibitor prevented not only an increase in albuminuria, but also glomerular histological changes in db/db mice without affecting blood glucose levels. Diabetic nephropathy is histologically characterized by thickening of glomerular basement membrane and expansion of glomerular mesangium (33, 35, 37) . Progression of the latter is considered to be responsible for the obliteration of capillary lumen, which leads to glomerulosclerosis and the decline of glomerular filtration rates (27, 34) . Although numerous in vivo studies in glomeruli of diabetic animals as well as in vitro studies in glomerular mesangial cells cultured under high glucose conditions have implicated the activation of PKC as an important causative factor in diabetic nephropathy (5), a long-term in vivo study to examine the effect of the PKC inhibition on diabetic glomerular histological abnormalities has not been undertaken. Since our previous studies indicated that the oral administration of a PKC ␤ inhibitor (LY333531) ameliorated early glomerular dysfunction such as glomerular hyperfiltration and albuminuria in STZinduced diabetic rats (19), we examined whether this inhibitor would have beneficial effects in a long-term in vivo study in db/db mice. We chose db/db mice to test whether glomerular PKC activation in this model for type 2 diabetes could be linked to glomerular abnormalities and glomerular mesangial expansion resembling that found in human diabetes (38, 39) .
Similar to a previous report (39) , the quantitative analysis in the present study revealed a 400% increase in mesangial matrix area in the diabetic db/db mice as compared with that in the nondiabetic db/m mice. As shown by the immunohistochemical analysis, mesangial expansion in db/db mice was accompanied by accumulation of ECM proteins such as fibronectin and type IV collagen. Treatment of db/db mice with the PKC ␤ inhibitor significantly reduced mesangial expansion and attenuated the increased expression of fibronectin and type IV collagen. An increase in the expression of mRNA for fibronectin and type IV collagen has been shown in glomeruli of STZ-induced diabetic animals (18, 40 -44) as well as in the cortex of db/db mice (39, 45) . We have recently shown that the PKC ␤ inhibitor can abrogate the increased mRNA expression of ECM proteins in parallel with the specific inhibition of glomerular PKC ␤ activation in STZinduced diabetic rats (18) . The area under the curve (AUC) in male mice treated with 30 mg/kg body weight/day of PKC ␤ inhibitor, LY333531 and its equipotent metabolite LY33852 was 3.472 M/h, which yields an average daily AUC of 145 nM (Dr. Carl Garner, personal communication). Extrapolating these data to the 10 mg/kg body weight/day Figure 5 . PKC ␤ inhibition prevents increases in fibronectin expression in db/db mice. The section fixed with 10% FM was used for an immunohistochemical study of fibronectin using a specific polyclonal anti-mouse fibronectin antibody, A852/R5H (Biogenesis, Poole, England). Immunostaining was performed by the streptavidin-biotin immunoperoxidase method using a histofine SAB-PO kit according to instructions of manufacture. Immunoreactive products were visualized using diaminobenzidine as a chromogen, and counter stained with methyl green. Enhanced expression of fibronectin in the glomeruli of db/db mice was prevented by treatment with the PKC ␤ inhibitor. A) db/m; B) db/m treated with the PKC ␤ inhibitor; C) db/db; D) db/db treated with the PKC ␤ inhibitor. dose used in the present study would predict an AUC of 1.15 M/h, with an average daily AUC of 48 nM. This plasma concentration of PKC inhibitory activity is specific for PKC ␤ isoform and should not significantly inhibit other PKC isoforms (19) . Thus, amelioration of mesangial expansion by the PKC ␤ inhibitor suggests that the reduction of diabetesinduced overexpression of fibronectin and type IV collagen may occur through the inhibition of glomerular PKC ␤ activation, although roles of other PKC isoforms remain to be clarified. The beneficial effect of PKC ␤ inhibition on the increased accumulation of ECM proteins in the mesangial area could be due to its direct effect on the production of ECM proteins by mesangial cells or though the production of TGF-␤. TGF-␤ has been recently implicated to mediate diabetes-or hyperglycemia-induced overproduction of ECM proteins, resulting in mesangial expansion (15, 46 -48) . Our present study has also demonstrated that the protein expression of TGF-␤ is enhanced in the glomeruli of db/db mice in association with accelerated mesangial expansion consisting of fibronectin and type IV collagen. Furthermore, we have found that this enhanced expression of TGF-␤ was inhibited by treatment with a PKC ␤ inhibitor, consistent with the attenuation of ECM overexpressions. In contrast to our findings, Cohen et al. (49) reported that TGF-␤ mRNA and protein in renal cortex from db/db mice did not differ from those in their nondiabetic littermate db/m mice, and urine and plasma concentrations of immunoreactive TGF-␤1 were reduced in db/db mice. However, Cohen et al. (49) concluded that TGF-␤ pathway was implicated as an important mediator in the increased gene expression of ECM by demonstrating up-regulation of TGF-␤ type II receptor mRNA and protein in db/db mice. The methods described in our study differ from those used by Cohen et al. For instance, the anti-TGF-␤ antibody in our study recognizes all forms of TGF-␤. In addition, we found the enhancement of TGF-␤ protein expression in glomeruli, whereas Cohen et al. examined the mRNA and protein expression in renal cortex in db/db and db/m mice. Thus, these differences in methodology and locus may explain the dissimilarity between these findings. Our findings in db/db mice thus appear to result from glomerular TGF-␤ mRNA overexpression or an excess of TGF-␤ protein trapped in the glomeruli. To clarify this issue, in situ hybridization studies for TGF-␤ isoforms are needed.
PKC activation might regulate the overexpression of TGF-␤ at a transcriptional level since its promoter contains activator protein 1 (AP-1) sites. AP-1 sites are activated by the proto-oncogenes complex, fosjun homodimers or heterodimers through a PKC-ERK dependent pathway (50, 51) . To examine this hypothesis, we recently provided evidence that ERK activities are enhanced in the glomeruli of STZinduced diabetic rats, and this enhancement was dependent on PKC activation (7). Thus, diabetesinduced TGF-␤ overexpression in the glomeruli of db/db mice might result from the enhancement of PKC-ERK activation and lead to the overexpression of ECM proteins, finally resulting in mesangial expansion. Alternatively, activation of PKC-ERK pathway could directly stimulate the production of ECM proteins. For example, the AP-1 complexes were shown to be able to increase the transcriptional activation of fibronectin gene (52) . Cyclic AMPresponsive elements (CRE) were found in the promoter region of fibronectin gene (53, 54) , and AP-1 complexes were shown to be able to activate CRE (55) . Indeed, phorbol esters and serum have been reported to enhance the gene expression of fibronectin by the activation of CRE (54). Thus, it is possible that diabetes-or high glucose-induced PKC-ERK activation could play a pivotal role in ECM overproduction in either a direct fashion or indirectly through TGF-␤ production.
Diabetic nephropathy is the leading cause of ESRD, requiring dialysis therapy in the Western and Asian countries (1). About 25-40% of patients . PKC ␤ inhibition prevents increases in TGF-␤ expression in db/db mice. The section fixed with 10% FM was used for an immunohistochemical study of TGF-␤ using a specific polyclonal anti-TGF-␤ antibody (R&D Systems Inc., Minneapolis). Immunostaining was performed by the streptavidin-biotin immunoperoxidase method using a histofine SAB-PO kit according to the manufacture's instruction. Immunoreactive products were visualized using diaminobenzidine as a chromogen and counterstained with methyl green. Enhanced expression of TGF-␤ in the glomeruli of db/db mice was prevented by treatment with the PKC ␤ inhibitor. A) db/m; B) db/m treated with the PKC ␤ inhibitor; C) db/db; D) db/db treated with the PKC ␤ inhibitor.
with type 1 and type 2 diabetes develop diabetic nephropathy 25 years after the onset of diabetes (56 -60) . Based on the results of cumulative epidemiological studies (2, 3) , it is evident that the most effective therapy to prevent the development and progression of nephropathy is to maintain normoglycemia. However, from these epidemiological studies, it is also evident that the maintenance of long-term normoglycemia is difficult in most subjects with type 1 or type 2 diabetes. Pancreatic transplantation is an alternative strategy to maintaining long-term normoglycemia. However, pancreatic transplantation is not available to the majority of diabetic patients worldwide. Therefore, efforts have been directed to clarify the responsible mechanisms by which diabetes causes diabetic nephropathy and identify the therapeutic strategies that could abrogate the development and progression of diabetic nephropathy. Our findings in the present study provide the first in vivo evidence that long-term PKC inhibition by the oral treatment with a PKC ␤ inhibitor can influence the development of diabetic nephropathy histologically without causing any obvious adverse effect and independent of glycemic control. Our results also suggest that a PKC ␤ inhibitor might be a new and novel approach for the treatment of diabetic nephropathy.
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